You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

Citation Tools

Article menu

Download PDFPDF

XML
Research Article
Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Zhang J, Larrocha PS, Zhang B, et al
Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy
Journal for ImmunoTherapy of Cancer 2019;7:223. doi: 10.1186/s40425-019-0693-y